A Study to Assess the Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin Administered as Microdoses in Subjects With Varying Degrees of Renal Insufficiency in the Presence and Absence of Rifampin

Trial Profile

A Study to Assess the Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin Administered as Microdoses in Subjects With Varying Degrees of Renal Insufficiency in the Presence and Absence of Rifampin

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Atorvastatin (Primary) ; Dabigatran etexilate (Primary) ; Midazolam (Primary) ; Pitavastatin (Primary) ; Rifampicin (Primary) ; Rosuvastatin (Primary)
  • Indications Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 11 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 16 Mar 2018 Planned primary completion date changed from 19 Jul 2018 to 30 Jul 2018.
    • 16 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top